STEAP1 CART
/ Promicell Therap, Fred Hutchinson Cancer Center
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
October 19, 2024
Engineering Next-Generation STEAP1 CAR T Cells: Development and Optimization for Enhanced Anti-Tumor Efficacy in Prostate Cancer
(PCF 2024)
- "Our research advances STEAP1-BBζ CAR-T cell therapy by addressing challenges such as antigen escape and functional exhaustion. Optimized PSMA CAR T cells exhibit enhanced anti-tumor efficacy, supporting the development of dual-targeting PSMA-STEAP1 CAR T cells. Additionally, our in vitro model and CRISPR screen identified genetic modifications that enhance metabolic fitness and CAR T cell activity."
CAR T-Cell Therapy • Clinical • IO biomarker • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Hematological Malignancies • Oncology • Prostate Cancer • Solid Tumor • CD4 • CD8 • IFNG • PSCA • STEAP1
September 19, 2024
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
(clinicaltrials.gov)
- P1/2 | N=48 | Not yet recruiting | Sponsor: Fred Hutchinson Cancer Center | Initiation date: Sep 2024 ➔ Dec 2024
Metastases • Trial initiation date • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor
October 03, 2024
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
(clinicaltrials.gov)
- P1/2 | N=48 | Recruiting | Sponsor: Fred Hutchinson Cancer Center | Not yet recruiting ➔ Recruiting
Enrollment open • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
May 06, 2024
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
(clinicaltrials.gov)
- P1/2 | N=48 | Not yet recruiting | Sponsor: Fred Hutchinson Cancer Center | Initiation date: May 2024 ➔ Sep 2024
Metastases • Trial initiation date • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor
February 01, 2024
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
(clinicaltrials.gov)
- P1/2 | N=48 | Not yet recruiting | Sponsor: Fred Hutchinson Cancer Center
New P1/2 trial • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor
1 to 5
Of
5
Go to page
1